Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc. is an American biotechnology company headquartered in San Diego, California. Founded in 1998 and taken public in 2004, the company is primarily focused on its proprietary and patented recombinant human hyaluronidase enzyme, rHuPH20. Its business spans two main areas: the development of oncology therapies designed to target the tumor microenvironment, and the licensing of its Enhanze drug delivery technology to other biopharmaceutical companies. Halozyme's most advanced proprietary product is Hylenex recombinant (hyaluronidase human injection), approved by the U.S. Food and Drug Administration in 2005 for use in subcutaneous fluid administration, dispersion and absorption of injected drugs, and subcutaneous urography. The company's development pipeline has concentrated on clinical and pre-clinical oncology candidates, most notably PEGPH20, a pegylated version of rHuPH20 that targets hyaluronan (HA)-high tumors. PEGPH20 was studied across multiple solid tumor types, including pancreatic cancer, non-small cell lung cancer (NSCLC), and gastric cancer, but in November 2019 Halozyme announced it had halted development of the drug. The Enhanze platform uses recombinant human hyaluronidase to degrade hyaluronan and aid the absorption and dispersion of co-administered injected drugs. Halozyme licenses Enhanze to a roster of biopharmaceutical partners—including Roche, Baxalta, Pfizer, Janssen, AbbVie, Bristol Myers Squibb, and Lilly—to enable conversion from intravenous to subcutaneous administration and dose optimization. Helen Torley has served as Chief Executive Officer and President since January 2014. The company remains active and publicly traded.

Halozyme Therapeutics, Inc. was founded in 1998 and went public in 2004. The company is headquartered in San Diego, California. Its business is primarily focused on its proprietary and patented recombinant human hyaluronidase enzyme, rHuPH20. The company's development pipeline has been concentrated in clinical-stage and pre-clinical-stage oncology products, including its proprietary investigational drug PEGPH20, a pegylated version of rHuPH20 that targets hyaluronan (HA)-high tumors. Halozyme has conducted clinical trials with PEGPH20 across multiple solid tumor types, including pancreatic cancer, non-small cell lung cancer (NSCLC), and gastric cancer, to test the drug's safety and efficacy. The company has one FDA-approved product, Hylenex recombinant (hyaluronidase human injection), approved on December 2, 2005. Halozyme also licenses its drug delivery technology Enhanze to other biopharmaceutical companies, including Roche, Baxalta, Pfizer, Janssen, AbbVie, Bristol Myers Squibb, and Lilly. In November 2019, Halozyme announced it had halted development of PEGPH20. Since January 2014, Helen Torley has been Chief Executive Officer and President of Halozyme.

• Company founded

• Went public

• Hylenex approved by FDA

• Helen Torley appointed CEO and President

• Announced halt of PEGPH20 development

Biotechnology company specializing in recombinant human hyaluronidase-based therapies and drug delivery technology licensing.

• Hylenex recombinant (hyaluronidase human injection)

  FDA-approved hyaluronidase injection indicated for subcutaneous fluid administration, dispersion and absorption of injected drugs, and subcutaneous urography.

• Enhanze

  Drug delivery technology using recombinant human hyaluronidase to degrade HA and aid absorption and dispersion of co-administered injected drugs; licensed to biopharmaceutical companies.

• PEGPH20

  PEGylated drug candidate based on rHuPH20 targeting HA-high tumors; development halted in November 2019.

• 2026.08.18

  Reported2026.08.18

  Halozyme Appoints Dannielle Appelhans to Board of Directors[3]Halozyme任命Dannielle Appelhans为董事会成员prnewswire.com

  Halozyme Therapeutics, Inc. announced the election of Dannielle Appelhans to its Board of Directors on August 18, 2026. Appelhans brings more than 20 years of executive leadership in biotechnology and pharmaceuticals, including operations, manufacturing, and supply chain expertise.

Read more

1. 1Halozyme - Wikipediaen.wikipedia.org
2. 2Halozyme Official Websitehalozyme.com
3. 3Halozyme任命Dannielle Appelhans为董事会成员prnewswire.com